The ongoing labor dispute at Samsung Biologics is raising concerns within and outside the bio industry as signs of a prolonged conflict emerge. Similar to the situation with Samsung Electronics, this issue should not be viewed merely as a wage negotiation for one company. Samsung Biologics symbolizes the South Korean bio industry, and any decline in its competitiveness could lead to a broader trust issue for K-Bio, especially as Chinese and Japanese firms aggressively pursue market share. A prolonged labor conflict could weaken South Korea's bio competitiveness even further.
The global biopharmaceutical CDMO (Contract Development and Manufacturing Organization) market is akin to a battlefield. While South Korean companies have been leading the market with impressive growth, recent developments show that Japanese and Chinese firms are catching up rapidly. Japan's Fujifilm has made aggressive investments to establish one of the largest biomanufacturing facilities in Europe, quickly rising to the top tier of global production capacity. Meanwhile, China's CL Biologics is rapidly expanding its production facilities, backed by substantial capital and government support.
It is crucial to note that this competition is not merely about production volume. Chinese and Japanese companies are expanding their reach not only in scale but also in technology and service areas, attracting global clients. These clients can easily switch to more stable and flexible production sources at any time.
At this juncture, the labor conflict at Samsung Biologics cannot be dismissed as an internal issue. Trust is the cornerstone of the bio CDMO industry. Global pharmaceutical companies do not simply contract based on the size of production facilities; they prioritize stable supply capabilities. They assess whether production processes remain consistent, deadlines are met, and quality is maintained under any circumstances.
Biomanufacturing is fundamentally different from traditional manufacturing. The cell culture process requires 24/7 real-time management. Any interruption in the process can lead to not just production delays but also the potential loss of entire batches, which could impact regulatory approvals. Therefore, global clients are particularly sensitive to production stability. Samsung Biologics' rise to become one of the world's largest CDMO companies is rooted in its foundation of stability and trust.
The Samsung Biologics union has engaged in partial strikes since April, followed by a full strike from May 1 to May 5, and has now entered a phase of legal compliance protests starting June 6. Reports indicate that discussions with management under government mediation have not progressed. The union's demands include a 30 million won incentive payment per person, a 14% average wage increase, a 20% profit-sharing bonus, and the establishment of fair personnel standards.
The ongoing legal compliance protests involve refusing to work on holidays and overtime, conducted within the legal framework. This has not completely halted production lines, making it difficult to accurately estimate the current financial losses. However, considering the nature of the bio industry, the more significant issue is the reduced ability to respond to unexpected variables rather than the immediate financial losses.
In biomanufacturing, sudden situations frequently arise. Global clients may request urgent orders, or adjustments to production schedules may be necessary. Maintaining process stability often requires overtime or holiday work. The concern is that if the current legal compliance protests continue for an extended period, the ability to respond to such situations could become increasingly difficult.
Ultimately, the CDMO industry relies heavily on trust with clients. It is essential to provide stable supplies when clients need them. However, if labor disputes lead to reduced production flexibility and weakened emergency response capabilities, global clients' anxiety will inevitably increase. Major pharmaceutical companies are highly sensitive to potential production disruptions and do not hesitate to consider alternative suppliers if signs of supply instability emerge.
An even greater issue is that once trust is shaken in the bio industry, it is incredibly challenging to restore. Relationships with clients built over years can be jeopardized by a single concern about supply disruptions. This is particularly true now, as Japanese and Chinese companies aggressively seek to secure clients. Competitors are likely closely monitoring the labor conflict situation in South Korea. From the clients' perspective, it is only natural to choose a stable supply chain rather than risk exposure.
What is needed now is not emotional confrontation but a perspective that considers the entire industry. Workers' rights must be respected, and demands for fair compensation are necessary. However, the bio industry has a strong national strategic industry character, unlike traditional manufacturing. Just as disruptions in semiconductor factories can impact the entire national economy, disruptions in biomanufacturing are directly linked to national industrial competitiveness. There is a need for a shared understanding that both labor and management must protect the future of the industry together.
The global CDMO market is not waiting. Japanese and Chinese companies are aggressively pursuing South Korea with substantial investments and strategies. Just a decade ago, K-Bio was on the periphery of the global market, but through bold investments, technological accumulation, and production competitiveness, it has risen to the forefront. Now, the greatest threat is not just external competitors. The moment internal fractures undermine industrial competitiveness, the opportunities and trust built over time can collapse in an instant. The repercussions will not be confined to Samsung Biologics alone but will likely lead to a decline in K-Bio's industrial competitiveness as a whole. This is why the Samsung Biologics situation should be viewed as a warning for the entire bio industry.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.